NEW YORK ( TheStreet) -- Clinical Data ( CLDA) was the biggest gainer among small-caps Monday afternoon, its shares soaring 55% to $23.30, after U.S. regulators approved its major depressive disorder treatment Viibryd. The biotech company said the drug would be available in U.S. pharmacies by the second quarter. Over 9 million shares changed hands.

Shares of Genoptix ( GXDX) jumped 26% to $24.83 on heavy volumes after Swiss pharma giant Novartis ( NVS) said it was acquiring the diagnostics laboratory for $470 million or $25 per share in an all cash deal.

Rexahn Pharmaceuticals ( RNN) shot up 20% to $1.57 after Israel-based Teva Pharmaceuticals ( TEVA) said it had acquired a 6% stake in the company at $1.69 per share.

Several solar stocks were shining on the bourses after Goldman Sachs added First Solar ( FSLR) to its conviction list. Shares of LDK Solar ( LDK) were surging 10.5% to $14.53. Solarfun Power ( SOLF), Trina Solar ( TSL) and ReneSola ( SOL) were also up sharply.

Shares of Depomed ( DEPO) were recovering Monday after plunging last week, rising 7.2% to $6.23. The stock took a hit last week after it said that Abbot Laboratories ( ABT) was reluctant to market its pain reliever drug.

Level 3 Communications ( LVLT), Dot Hill Systems ( HILL), Pluristem Therapeutics ( PSTI) and ATP Oil and Gas ( ATPG) were among the other major gainers on Monday.

-- Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Insider Trading, David Sokol: Hot Trends

Insider Trading, David Sokol: Hot Trends

FDA Chemist Charged With Insider Trading

FDA Chemist Charged With Insider Trading

Biotech Stock Mailbag: Exact Sciences

Biotech Stock Mailbag: Exact Sciences

Clinical Data Stock Falls On Unusually High Volume (CLDA)

Clinical Data Stock Falls On Unusually High Volume (CLDA)

Forest Labs 'Takes Under' Clinical Data

Forest Labs 'Takes Under' Clinical Data